131 Dartmouth St, Suite 502
47 articles with Cerevel Therapeutics
Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson’s Disease
Studies to Enroll Approximately 1,200 Patients to Determine Effectiveness of Tavapadon Across the Full Spectrum of Early- and Late-Stage Parkinson’s
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy
Cerevel Therapeutics announced results of a Phase 1 dose-escalation clinical trial1 evaluating the safety, tolerability and pharmacokinetics of multiple repeated doses of CVL-865 in healthy volunteers.
Cerevel Therapeutics to Present Safety, Tolerability, and Pharmacokinetics Results From Phase 1 Trial of CVL-865
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, will present new data from a Phase 1 dose-escalation clinical trial evaluating the safety, tolerability, and pharmacokinetics of multiple repeated doses of CVL-865 (formerly PF-06372865) in healthy volunteers
11/22/2019Pharma and biotech companies strengthen their leadership teams and boards with this week's appointments.
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Bryan K. Phillips as chief legal officer.
Cerevel Therapeutics Announces the Appointment of Seasoned Finance Executive, Gabrielle Sulzberger, to its Board of Directors
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has added Gabrielle Sulzberger to serve as an independent member of its Board of Directors